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1. Introduction  
Alpha-1 antitrypsin deficiency (AATD) affects approximately 3 million people worldwide (1), 
and yet its pathophysiology is poorly understood. In the lung, lack of alpha-1 antitrypsin 
leads to proteolytic damage to the connective tissue matrix, resulting in emphysema in 
approximately 75% of PiZZ patients (2). Point mutations lead to altered folding of the protein 
during biosynthesis, resulting in misfolded proteins being retained within hepatocytes (3). 
The aggregation of antitrypsin polymers within the endoplasmic reticulum (ER) of liver cells 
forms periodic acid-Schiff positive inclusions, which cause endoplasmic reticular stress, 
mitochondrial dysfunction and trigger autophagy. Hepatocytes with less abundance of 
mutant Z protein proliferate, and this chronic cycle of cell death and regeneration activates 
hepatic stellate cells and initiates hepatic fibrosis (4), although the true mechanism of injury 
is yet to be fully elucidated .  A conundrum in AATD remains the phenotypic variability in 
both lung and liver disease.  Children may experience jaundice during infancy but have no 
further complications, whilst others develop liver cirrhosis and require liver transplantation. 
The ability to predict which individuals are at highest risk of developing significant liver 
disease would be useful clinically for prognostic purposes, planning of clinical services, and 
influencing lifestyle behaviours where appropriate. For example, in AATD-related lung 
disease, cigarette smoking is the greatest predictor of lung function deterioration, and so 
smoking cessation is strongly advised in these individuals.  Here we summarise the patterns 
of presentation and prognosis in AATD-related liver disease in children and adults, and 
review the evidence for factors which may be influential in disease progression. 
 
2. AATD in Children  
AATD commonly presents in infancy with jaundice (5, 6), but it can also present with 
neonatal hepatitis, hepatosplenomegaly, or gastrointestinal haemorrhage without jaundice 
(5).  From presentation, the disease takes a varied and fluctuating course, with only a small 
proportion of children (less than 1%) developing liver failure in infancy (5, 6), with others 
making a full recovery.  A proportion (approximately 1%) of those children presenting in 
infancy recover to enjoy years of good health whilst later on developing severe disease (7) 
and require liver transplantation. This commonly occurs between the ages of 4 and 8 (8), but 
sometimes later on in the second decade of life (9, 10). Other children have no signs of 
disease during infancy but are diagnosed incidentally later in childhood following abnormal 
liver biochemistry tests (10, 11) in response to screening of family members of an affected 
individual (12). Others can present with advanced or even decompensated liver disease (11, 
13).  
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AATD more commonly affects the Caucasian population, and in a recent systematic review, 
97% of children diagnosed with the condition were of Caucasian origin (9).  Interestingly, 
although males comprise only 35% of children diagnosed with AATD, boys accounted for 
over 60% of children undergoing liver transplantation for AATD, suggesting that disease 
progression is more likely in males  (9).  
Our recent systematic review found that 8% of children with polymerogenic AATD developed 
liver cirrhosis, and 16% required liver transplantation (9). The discrepancy between these 
figures is most likely due to ascertainment bias, with a large number of studies reviewed 
arising from liver transplant centres, and so it seems likely that the proportion of children with 
AATD that will develop cirrhosis and require liver transplantation is about 10%. The reason 
that such a small proportion of individuals with polymerogenic AATD develop significant liver 
disease is unknown.  Some studies have suggested that differences in the ability of 
hepatocytes to transport polymerised proteins out of ER for degradation by proteasomes, or 
in hepatocyte autophagic degradation pathways between individuals, may play a role (14). In 
common with many chronic diseases it could be that genetic modifiers play a role, as they do 
in AATD lung disease (3) 
Multiple studies have investigated potential predictive factors for poor prognosis in children 
with AATD related liver disease, but results have been mixed. Raised aspartate 
aminotransferase (AST) at presentation, particularly in combination with gamma-glutamyl 
transferase (GGT), was found to be a risk factor for requiring liver transplantation later in life 
in one study (11), but these findings were not replicated in other studies investigating liver 
biochemistry (13).  Several studies identified jaundice, either at presentation (12, 15) or 
prolonged (>6 months) in those with neonatal hepatitis (11) as risk factors.  However, in one 
study infants with severe prolonged jaundice (conjugated serum bilirubin above 2.0 
mg/100ml at two to three months of age) went on to make a complete recovery, and another 
study looking at jaundice early in life made the same findings (16). 
Some studies have proposed liver biopsy findings as potential predictors for development of 
liver disease, albeit with mixed results. Portal fibrosis and paucity of bile ducts are the 
features most consistently found at liver biopsy in infants who progress to liver cirrhosis (17) 
and/or require liver transplantation (9, 11). 
For children with progressive disease that do require liver transplantation, outcomes are 
excellent, matching those for other indications, with no recurrence of liver disease and no 
development of AATD- related lung disease (11, 13, 18).   
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3. AATD in Adults 
As in children, disease severity and mode of presentation varies widely in adults. AATD may 
be diagnosed incidentally in an otherwise unaffected individual whilst others develop 
cirrhosis and require liver transplantation (9). Adults requiring transplantation for AATD 
related liver disease have a median age of between 34 and 54 (9) suggesting that severe 
disease presents before the 5th decade in adults. As with children, the majority (93%) of 
adults with AATD related liver disease are Caucasian. Disease progression occurs more 
commonly in males, despite the diagnosis being made equally in women and men (53% 
male), and yet 73% of those requiring transplantation are male (9).  
Increased body mass index (BMI) has been found to be a risk factor for requirement for liver 
transplantation in individuals with AATD related liver disease (10), as has concurrent viral 
infection (10, 19), and alcohol consumption (10, 20) in some studies.  It seems likely that 
concurrent liver injury from such factors accelerates disease progression in AATD, however, 
cofactors are not identified in all adults with AATD related liver disease.  
Whereas hepatocellular carcinoma (HCC) is not reported in children with AATD, its 
incidence in adults is similar to that for cirrhosis of other aetiologies, with an overall 
incidence of 1.3%. 
Just over 10% of adults presenting with AATD related liver disease develop liver cirrhosis 
and require transplantation, and outcomes following transplantation for AATD related 
disease match those for other aetiologies (8, 18). 
In summary, although there are recognised patterns of presentation for AATD-related liver 
disease, it can present at any age, and across a spectrum of disease severity. Whilst serum 
markers such as AST, GGT and bilirubin may be useful to predict disease progression, 
these factors, together with others such as biopsy findings, require more robust investigation 
through prospective studies. In the mean-time, use of non-invasive tools such as transient 
elastography (21) and Enhanced Liver Fibrosis (ELF) (22) test may help to identify those 
individuals who have liver fibrosis and are at risk of progression to cirrhosis, although 
research is required to validate this approach this cohort of patients. Finally, a better 
understanding of the pathophysiology of AATD-related liver disease may help not only to 
identify why certain individuals are more susceptible, but also contribute to the development 
of much needed treatment options.   
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